NCM
MIST icon

Nantahala Capital Management’s Milestone Pharmaceuticals MIST Stock Holding History

Nantahala Capital Management’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,445,264
Closed -$3.41M – 155
2024
Q4 		$3.41M Sell
1,445,264
-304,736
-17% -$523K 0.15% 97
2024
Q3 		$2.66M Hold
1,750,000
– – 0.13% 92
2024
Q2 		$2.31M Hold
1,750,000
– – 0.14% 86
2024
Q1 		$3.13M Buy
+1,750,000
New +$2.84M 0.18% 79

Other funds holding MIST

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $265M AUM 98.61% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nantahala Capital Management's MIST Position: Q1 2025 in Review

Nantahala Capital Management sold out of Milestone Pharmaceuticals (MIST) in Q1 2025, closing a stake of 1,445,264 shares — an estimated $3.41M sold.

Nantahala Capital Management first reported a position in MIST in Q1 2024 and held it in 4 quarters. The position peaked at $3.41M in Q4 2024. 43 funds tracked by Wall St. Rank hold MIST as of Q1 2025.

  • Nantahala Capital Management reported no remaining Milestone Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Nantahala Capital Management sold 1,445,264 Milestone Pharmaceuticals shares in Q1 2025, an estimated $3.41M.
  • Nantahala Capital Management first reported a position in Milestone Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Nantahala Capital Management's Milestone Pharmaceuticals position peaked at $3.41M in Q4 2024.
  • 43 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q1 2025.

Based on Nantahala Capital Management's 13F filing for Q1 2025, filed 15 May 2025.